Dental laser developer and manufacturer BIOLASE, Inc. announced the price of its public offering of 16,000,000 units. Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $7 million. The offering is expected to close on Feb. 15, subject to customary closing conditions. It follows BIOLASE's close of its $4.5 million underwritten public offering (Series J convertible redeemable preferred stock and warrants) last summer. Per the latest offering, each unit is to consist of one share of common stock (or one pre-funded warrant to purchase one share of common stock); one Class A Warrant to purchase one share of common stock; and one Class B Warrant to purchase one share of common stock. Each unit is being sold at an effective public offering price of $0.44. The Class A Warrants will be immediately exercisable at a price of $0.66 per share.